[REVISION HISTORY]

BridgeBio Pharma Q2 financial performance

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-11 17:03 UTC → 2026-08-12 17:02 UTC · added ~~removed~~

BridgeBio Pharma reported second-quarter results highlighting significant growth in net product revenue, reaching $222.4 million compared to $71.5 million in the previous year. This growth was primarily driven by the ATTR cardiomyopathy treatment, Attruby. CEO Neil Kumar described the company as being in a “transition period” marked by the commercial success of Attruby and the progression of late-stage programs. The company reaffirmed its global sales guidance for Attruby and Beyonttra, projecting worldwide net sales to exceed $1 billion for the year. To fund commercial and pipeline investments, BridgeBio completed a $1 billion preferred equity raise. The company is also preparing for three potential product launches by mid-2027, with regulatory submissions currently underway for programs targeting achondroplasia, autosomal dominant hypocalcemia type 1, and limb-girdle muscular dystrophy type 2I. In subsequent financial reporting, BridgeBio reported revenue of $243.68 million, which exceeded the $220.91 million estimate, though its earnings per share (EPS) of ($0.78) missed the consensus estimate of ($0.58). Management noted that Attruby’s growth is being led by first-line, treatment-naive patients and highlighted data suggesting the treatment may offer kidney-protective effects.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.